In AML patients before and after initiation treatment with decitabine, no significant changes were observed for all immune cell populations post-decitabine treatment including CD4+ or CD8+ T cells, Tregs, NK cells, NKT cells, B cells, DCs, and MDSCs. This evidence concerns the gene CD4 and acute myeloid leukemia.